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Patients with chronic viral hepatitis display increased expression of Foxp3 in liver, suggesting that Tregs expansion contributes
to persistent infection. The purpose of this study was to elucidate whether the expression of Foxp3 relates not to the viral
infectionbuttotheresultingliverinﬂammation.Liverbiopsiesobtainedfrom69individuals(26chronicHBVhepatitis,14chronic
HCV hepatitis, 11 nonalcoholic fatty liver disease, 8 autoimmune diseases, 2 methotrexate-related toxicity, and 8 controls) were
examined, by qRT-PCR, for the mRNA expression of Foxp3, IL-10, TGF-β1, Fas, FasL, TRAIL, caspase-3, TNF-α,I F N - γ, and IL-1β.
Signiﬁcant increase of Foxp3 was observed in all disease groups compared to controls, which was positively correlated with the
intensity of inﬂammation. The expression of the apoptosis mediators Fas, FasL,a n dTRAIL, but not of IL-10 and TGF-β1,w a s
also signiﬁcantly elevated. Our ﬁndings indicate that, independently of the initial inducer, liver inﬂammation is correlated with
elevated expression of apoptosis mediators and is followed by local Treg accumulation. Further research towards the elucidation
of the underlying casual relationships is required, in order to clarify whether our results signify the existence of a uniform Treg-
mediated regulatory mechanism of apoptosis-induced inﬂammation.
1.Introduction
T regulatory cells (Tregs) are important mediators of immu-
ne suppression, and their presence prevents reactions against
self by inducing regulatory signals to antigen presenting cells
(APCs) and/or eﬀector T cells [1, 2]. Their ablation increases
the risk of autoimmunity [3] whilst, on the contrary, their
signals could also aﬀect nonautoreactive clones, leading to
inhibition of antineoplastic, antimicrobial, antiparasitic, and
antiviral immune responses [1, 4, 5]. Accumulating evidence
indicates that patients with chronic viral hepatitis display
increased numbers of Tregs (both natural and inducible)
in peripheral blood [6–8]o rl i v e r[ 9–11], which in turn
exertasuppressivefunctionagainstspeciﬁchepatitisCvirus-
(HCV-) or hepatitis B virus- (HBV-) T eﬀector clones in
vitro [6–10]. Thus, it has been suggested that the expansion
of Tregs during viral hepatitis may contribute to an inade-
quate immune response, causing persistent viral infection.
However, the precise role of Tregs in the pathogenesis of
chronic hepatitis is the subject of intense debate, since it
has been demonstrated that Tregs suppress the function
and the expansion of virus-speciﬁc T eﬀector cells ex vivo,
irrespective of the patients having chronic or resolved virus
infection [11, 12].
Herein, we describe an mRNA expression study in biopsy
material scheduled to further elucidate the role of Tregs in
the pathogenesis of liver damage in chronic viral HBV and
HCV hepatitis. Bearing in mind that recent structural and2 Mediators of Inﬂammation
Table 1: Clinicopathological and serological data of the patients of the study.
Normals
Chronic HBV hepatitis Chronic HCV
hepatitis NAFLDa Autoimmune
diseasesb
MTX-related
toxicityc Diagnosis Relapse
N o . 81 971 4 1 18 2
Sex (M/F)d 5/3 9/10 4/3 11/3 6/5 2/6 0/2
Age (years)
(mean, range) 53.3 (27–67) 49.3 (24–64) 48.6 (22–65) 39.6 (27–50) 41.9 (21–66) 56.8 (37–73) 66 (60–72)
AST (U/μL)e
(mean, range) 46.6 (42–56) 185 (17–1969) 76.6 (31–277) 69.5 (24–218) 34.9 (19–63) 66.5 (30–225) 32.5 (24–41)
ALT (U/μL)f
(mean, range) 55 (48–70) 193 (15–1478) 102 (32–332) 91.2 (32–213) 58.8 (15–141) 65.5 (31–212) 28.5 (17–40)
Inﬂammation
gradeg
I - 0 8 ——— 3 ——
I-1 — 4 — 2 3 — 2
I - 2 — 8665 — —
I - 3 —5 1 6—3—
I - 4 —2— — —1—
Fibrosisg (mean,
range) 0 3.4 (0–6) 3.4 (1–5) 2.3 (1–4) 0.5 (0–2) 2.8 (0–6) 1 (1–1)
HAI score
(mean, range) 7.52 (1–15) 7.57 (5–11) 7.21 (2–12)
Viral load
(mean, range)
79.8 Meq/mL
(<0.01–21)
6.39 Meq/mL
(<0.01–4.5)
1.16 ×
106 IU/mL
(0.06–6.2)
aNAFLD: nonalcoholic fatty liver disease; bautoimmune diseases refers to autoimmune hepatitis (4 patients) and primary biliary cirrhosis (4 patients); cMTX:
methotrexate; dM: male; F: female; eAST: aspartate aminotransferase; fALT: alanine aminotransferase; ginﬂammation grade (I-0: without inﬂammation, I-1:
minimal, I-2: mild, I-3: moderate, and I- 4: marked) and ﬁbrosis stage were assessed as presented in Section 2.
molecular studies suggest apoptosis, rather than necrosis,
being the mechanism of liver cell death in chronic viral
hepatitis [13, 14], the expressions of forkhead box P3
(Foxp3) gene, characterizing naturally occurring CD4+ Tregs
(nTregs) [1], as well as that of inteleukin-10 (IL-10)a n d
transforming growth factor-β1( TGF-β1), characterizing Tr1
and Th3 inducible Tregs (iTregs) [15], respectively, were
examined in relation to the expression of major apoptosis
mediators, namely, Fas, Fas Ligand (FasL), tumor necro-
sis factor-alfa (TNF-α), and tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL). Furthermore, in order
to clarify whether the expansion of Tregs is a characteristic
ﬁnding of chronic viral hepatitis, we examined Foxp3
expression in liver biopsies of patients with other hepatic
diseases, including nonalcoholic fatty liver disease (NAFLD),
autoimmune hepatitis, primary biliary cirrhosis, and liver-
toxicity induced by methotrexate. Correlations with the
grade of inﬂammation and ﬁbrosis were also investigated
in order to identify its possible interaction with the above
factors towards the progression of liver damage.
2.MaterialandMethods
2.1. Patients. Liver biopsy specimens obtained from 26
patientswithchronicHBVhepatitis(CHB)(4withcirrhosis)
and 14 with chronic HCV hepatitis (CHC) were examined.
Amongst CHB patients, 19 were newly diagnosed and 7 were
responders under treatment for 48 weeks with Peg-IFNa2a
or antivirals and relapse after treatment withdrawal for 24
weeks. No patient presented with coinfection with other
hepatitis viruses (types A, D, and E) or superinfection with
HIV. Results were compared with those obtained from the
examination of biopsies from 11 patients with nonalcoholic
fatty liver disease (NAFLD). Liver biopsies from 8 patients
withautoimmunehepaticdiseases(4withautoimmunehep-
atitisandcirrhosisand4withprimarybiliarycirrhosis,PBC)
and 2 patients with rheumatoid arthritis and methotrexate-
(MTX-) related hepatotoxicity were also analyzed. None of
the patients were receiving antiviral or immunomodulatory
treatment during the last 3 months prior to liver sampling,
except for the 2 patients with rheumatoid arthritis who
were receiving MTX. Eight individuals submitted to liver
biopsy due to a mild increase of aminotransferases but
without liver necroinﬂammatory and architecture changes
(histologynegativefordisease)servedascontrols.HBVDNA
and HCV RNA quantiﬁcation was performed by the use
of the bDNA assay V2.0 (Bayer, Siemens) and the Cobas
Amplicor system (Roche Molecular Systems), respectively.
Demographic, clinicopathologic and serologic data of the 69
analyzed subjects are summarized in Table 1.
Each liver biopsy specimen was separated into two
parts. One of them was immediately ﬁxed in 10% formalinMediators of Inﬂammation 3
solution for diagnostic histological examination, and the
other was snap frozen and stored at −80◦C until further use.
Formalin-embedded sections were stained by haematoxylin-
eosinandMasson’strichrome.Twoindependentpathologists
assessed and scored each biopsy, and discrepancies were
further evaluated by an expert pathologist. In patients with
viral hepatitis, the histological activity index (HAI) and
the staging of ﬁbrosis (0–6) in formalin-ﬁxed tissues were
assessed according to the modiﬁed HAI scoring by Ishak et
al. [16]. In patients with NAFLD, the necroinﬂammatory
grade and the ﬁbrosis score (0–4) were assessed according to
the scoring by Brunt et al. [17]. According to the intensity
of liver inﬂammation biopsies, patients were classiﬁed as I-
0 (absent inﬂammation), I-1 (minimal, HAI score 1–4 and
mild grade inﬂammation for NAFLD), I-2 (mild, HAI score
5–8andmoderate-Igradewithminimalportalinﬂammation
for NAFLD), I-3 (moderate, HAI score 9–12 and moderate-
I Ig r a d ew i t hm a r k e dp o r t a li n ﬂ a m m a t i o nf o rN A F L D ) ,
and I-4 (marked, HAI score 13–18 and severe grade for
NAFLD) (Table 1). For patients with autoimmune hepatitis,
the inﬂammation grade and ﬁbrosis stage were estimated by
morphological criteria similar with CHB and CHC patients
and stratiﬁed accordingly, while, for patients with MTX-
related hepatotoxicity, the inﬂammation grade and ﬁbrosis
stage were assessed and stratiﬁed similar to the patients with
NAFLD (Table 1). However, patients with PBC, two of them
with stage 1 and two with stage 3, according to Ludwig et
al. [18]a n dS c h e u e r[ 19], were not estimated in the above
stratiﬁcation grades, because of the distinct pathological
ﬁndings of the disease.
Informed consent was obtained by all participants, and
the study was approved by the Institutional Review Board.
2.2. Quantitative Real-Time Reverse-Transcriptase PCR (qRT-
PCR). TotalRNAwasisolatedfromstoredliversamplesafter
homogenization, using TRI (Ambion, Austin, USA), accord-
ing to manufacturer’s instructions. cDNA was reversed
transcribed from 1μg of the RNA, using a random 6-mer
oligonucleotide primer (50pmol/μL )( R o c h e ,U S A )a n dM -
MLV reverse transcriptase (Invitrogen, UK), according to
manufacturer’s instructions.
The mRNA levels of ten genes, namely, Foxp3, Fas, FasL,
TRAIL, caspase-3, IL-10, TGF-β1, TNF-α, interferon-gamma
(IFN-γ), and interleukin-1beta (IL-1β), were determined
in a qRT-PCR reaction using Platinum-SYBR-Green PCR
Supermix (Invitrogen, UK), in the automated thermocycler
RotorGene 6000 (Corbett Life Science, Sydney, Australia).
The beta-2-microglobulin (B2M) gene was used as an
endogenous control for sample normalization (reference
gene). An 1/20 aliquot of the cDNA reaction product was
used in duplicate qRT-PCR reactions, and all measurements
were averaged. Primers were commercially obtained by
SABiosciences (Frederick, MD, USA). Thermocycler condi-
tions for the Foxp3, TGF-β1, caspase-3, TNF-α,a n dB2M
genes included an initial holding at 50◦Cf o r2 m i na n d
subsequently at 95◦C for 2min, followed by 40 cycles at
95◦C for 15sec and 60◦C for 60sec. For the Fas, FasL,
IL-10,a n dIFN-γ genes, three-step PCR was performed
with annealing at 55◦C( f o rFas, FasL,a n dIL-10)o r5 8 ◦C
(for IFN-γ) for 15sec and extension at 72◦C for 30sec
(denaturation and cycles were similar as for the other genes).
The eﬃciency of each qRT-PCR reaction ranged between
0.9 and 1.05. In order to verify the speciﬁcity of the PCR
products, melting curve analysis was performed from 65◦C
to 95◦Cw i t h0 . 1 ◦C/sec intervals and stepwise ﬂuorescence
acquisition. Relative quantiﬁcation and calculation of the
range of conﬁdence were performed using the comparative
ΔΔCT method, as described in [20] .T h er e l a t i v ee x p r e s s i o n
of each gene is presented as a multiple of the respective gene
expression in the sample of a normal control, who presented
with the lowest levels of aminotransferases. Expression data
of this patient (expression = 1, for all genes) were, therefore,
excluded from the statistical analysis.
2.3. Western Blot Analysis. The FOXP3 protein expression
was determined in randomly selected samples from 7
patients with hepatic diseases (3 with CHB, 2 with CHC,
and 2 with NAFLD) and 2 normal controls, using an anti-
FOXP3 mouse monoclonal antibody (ab22510) from Abcam
(Cambridge, UK). GAPDH (rabbit polyclonal, code: 2275-
PC-100; Trevigen, Gaithersburg, Md, USA) served as a
loading control, using an ultraviolet detection system (West-
ernDot 625 Goat Anti-Rabbit Western Blot Kit; Invitrogen),
according to manufacturer’s recommendations.
2.4. Statistical Analysis. For basic statistical calculations,
Foxp3, IL-10, TGF-β1, Fas, FasL, TRAIL, caspase-3, TNF-α,
IFN-γ,andIL-1βexpressionlevelsweretreatedascontinuous
variables. Diﬀerences of gene expression between disease
groups were analyzed by the nonparametric Mann-Whitney
U test. The association of the above parameters with inﬂam-
mation and ﬁbrosis grade was tested with Kruskal-Wallis H
test. Sprearman’s rank correlation coeﬃcient was used to
estimate the correlations of the expression among the afore-
mentioned genes, as well as the correlations of gene expres-
sions with aminotransferases levels or viral load. All statisti-
c a lc a l c u l a t i o n sw e r ep e r f o r m e db yt h eu s eo fS P S S( v e r s i o n
16.0, Chicago, Il, USA). Diﬀerences were considered statisti-
cally signiﬁcant when the P value (two sided) was <. 05.
3. Results
3.1. Gene Expression in Relation to Liver Diseases. As shown
in Table 2 and Figure 1, patients with CHB and CHC as
well as those with the other hepatic diseases (NAFLD,
autoimmune hepatitis, PBC, and MTX-related hepatotox-
icity) presented a statistically signiﬁcant increase of Foxp3
mRNA levels compared to normal controls. In none of the
patient groups, Foxp3 expression correlated with the alanine
aminotransferase(ALT)oraspartateaminotransferase(AST)
levels and the viral load (serum HBV DNA or HCV
RNA). The expression of FOXP3 was also conﬁrmed by
immunoblotting (Figure 1).
To ascertain whether the expression of speciﬁc apoptosis
mediators was altered, the mRNA levels of Fas, FasL,
TRAIL, TNF-α,a n dcaspase-3 were examined. A statistically
signiﬁcant increase of the mRNA expression of FasL was
found in liver biopsies from all patient groups compared4 Mediators of Inﬂammation
Table 2: Relative expression of the examined genes.
Gene Normals Chronic HBV hepatitis Chronic HCV
hepatitis NAFLDb Autoimmune
diseasesc
MTX-related
toxicityd
(no. 8) Diagnosis
(no. 19)
Relapse
(no. 7) (no. 14) (no. 11) (no. 8) (no. 2)
Mean ± S.D. Mean ± S.D.
(P valuea)
Mean ± S.D.
(P valuea)
Mean ± S.D.
(P valuea)
Mean ± S.D.
(P valuea)
Mean ± S.D.
(P valuea) Mean ± S.D.
Foxp3 1.11 ± 0.71 20.3 ± 16.0
(<.001)
10.4 ± 5.47
(.001)
12.7 ± 12.3
(.001)
18.4 ± 11.9
<.001
16.0 ± 15.2
(.001) 28.4 ± 27.8
TGF-β11 . 5 6 ± 1.49 1.10 ± 0.84
(.710)
0.53 ± 0.31
(.053)
0.73 ± 0.58
(.065)
1.60 ± 1.01
(.620)
1.43 ± 1.04
(.834) 0.72 ± 0.17
IL-10 1.50 ± 1.02 0.66 ± 1.33
(.011)
0.20 ± 0.24
(.016)
0.48 ± 0.77
(.017)
0.79 ± 0.77
(.131)
0.64 ± 0.94
(.093) 0.59 ± 0.62
Fas 0.82 ± 0.24 2.25 ± 0.70
(<.001)
2.12 ± 0.78
(.003)
1.55 ± 1.07
(.179)
3.51 ± 1.17
(<.001)
1.56 ± 0.94
(.132) 4.14 ± 0.41
FasL 1.05 ± 1.47 4.20 ± 2.05
(.001)
3.05 ± 1.98
(.028)
4.20 ± 4.09
(.004)
3.94 ± 4.42
(.004)
4.33 ± 3.69
(.008) 0.49 ± 0.39
TRAIL 2.89 ± 2.04 7.28 ± 4.34
(.007)
11.3 ± 6.29
(.015)
8.86 ± 4.56
(.001)
15.3 ± 6.64
(<.001)
3.52 ± 2.11
(.355) 15.3 ± 12.7
Caspase-3 1.87 ± 1.85 1.13 ± 0.74
(.915)
0.76 ± 0.43
(.366)
1.66 ± 1.34
(.700)
1.97 ± 1.05
(.283)
3.19 ± 2.23
(.093) 2.28 ± 0.66
TNF-α 3.43 ± 4.70 1.77 ± 3.12
(.307)
1.54 ± 1.93
(.201)
2.73 ± 3.58
(.544)
8.17 ± 11.0
(.480)
6.63 ± 9.11
(.186) 1.21 ± 0.93
IFN-γ 1.92 ± 1.77 5.47 ± 5.99
(.202)
4.17 ± 2.46
(.186)
2.19 ± 1.77
(.628)
4.18 ± 4.93
(.572)
8.43 ± 7.25
(.059) 0.37 ± 0.26
IL-1β 1.37 ± 1.05 0.51 ± 1.39
(.022)
0.41 ± 0.66
(.055)
0.33 ± 0.26
(.042)
0.99 ± 0.95
(.322)
1.15 ± 1.12
(.571) 0.30 ± 0.23
aStatistical signiﬁcance refers to comparison with the expression levels in the normal controls (Mann-Whitney U test); bNAFLD: nonalcoholic fatty liver
disease; cautoimmune diseases group consists of 4 patients with autoimmune hepatitis and 4 with primary biliary cirrhosis; dMTX: methotrexate.
to normal controls (Table 2). Furthermore, Fas expression
was found signiﬁcantly increased in patients with CHB and
NAFLD, while TRAIL expression was signiﬁcantly increased
in all patients, except of those with autoimmune diseases
(Table 2). Positive correlations were observed between the
intrahepatic expression levels of Foxp3 with the expression
of Fas (P = .014), FasL (P < .001) and TRAIL (P = .003)
(Figure 2), Fas and TRAIL (P < .001), and FasL and IFN-γ
(P < .001), irrespective of the cause of liver damage (viral,
NAFLD, autoimmunity, MTX).
Patients with CHB and CHC displayed an approximately
3-fold signiﬁcant decrease of IL-10 expression compared to
normal controls (Table 2). IL-10 expression levels in these
groups of patients were not signiﬁcantly diﬀerent from
those of NAFLD patients. Compared to normal controls,
NAFLD patients, as well as those with autoimmune hepatic
diseases and MTX-related toxicity, presented with lower IL-
10 expression levels that, however, did not reach the level of
statistical signiﬁcance (Table 2). Moreover, IL-1β transcripts
were signiﬁcantly decreased than those of normal controls in
the groups of CHB and CHC patients at diagnosis (Table 2).
No signiﬁcant diﬀerence in the expression of TGF-β1
w a so b s e r v e db e t w e e nt h ev a r i o u sg r o u p so fp a t i e n t sw i t h
liver diseases and normal controls (Table 2). However, a
signiﬁcant positive correlation between the expression levels
of TGF-β1 and those of Fas, IL-10, TNF-α, and IL-1β (P
< .05, in all cases) was found.
Tothispoint,itmustbeunderlinedthatoneCHBpatient
with very high Foxp3 mRNA levels (25-fold higher than that
of the reference sample) also displayed a high expression of
IL-10 and TGF-β1 (approximately 6-fold and 4-fold higher
than that of the reference sample, resp.). These ﬁndings were
conﬁrmed in repeated Q-RT-PCR analyses, and this patient
did not diﬀer from the other CHB patients, in any clinical or
laboratory parameter.
Finally, the expression levels of all genes in the post-
treatment biopsies obtained from 7 CHB patients during the
relapse of the disease did not diﬀer from their expression in
CHB patients at diagnosis.
3.2. Gene Expression in Relation to the Intensity of Inﬂam-
mation and Fibrosis. Taking into account that no striking
diﬀerences were observed between the various groups of
patients with respect to the expression of the analyzed genes,
we considered all subjects of the study as a whole group,
in an attempt to investigate possible relations between the
expression of the genes and the intensity of inﬂammation.
In relation to the intensity of inﬂammation, Foxp3
exhibited a statistically signiﬁcant increase of expression
from normal liver to severe inﬂammation (Figure 3). ThisMediators of Inﬂammation 5
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Figure 1: Expression of Foxp3 in diﬀerent hepatic diseases.
(a) Boxplot diagram of the relative expression of Foxp3 in the
diﬀerent disease subgroups (CHB: chronic HBV hepatitis, CHB∗∗:
chronic HBV hepatitis at relapse, CHC: chronic HCV hepatitis,
NAFLD: non-alcoholic fatty liver disease, AD: autoimmune dis-
eases/autoimmune hepatitis and primary biliary cirrhosis, and NC:
normal controls). (b) Western blot analysis of the expression of
FOXP3 and GAPDH. Lane 1: patient with CHC; Lanes 2 and 3:
patients with CHB; Lane 4: patient with NAFLD; Lane 5: patient
withautoimmunehepatitis;Lanes6–8:normalcontrols;M:SeeBlue
Plus2 Prestained Standard (Invitrogen, UK).
pattern of expression was nearly similar for FasL (Figure 3).
On the other hand, Fas and TRAIL displayed a diﬀerent
pattern of expression, where, compared to I-0 subjects
(without macroscopic evidence of inﬂammation), patients
with minimal to moderate inﬂammation (I-1 to I-3) exhib-
ited a statistically signiﬁcant increase of expression that
returned to those of I-0 subjects, as inﬂammation became
severe (I-4) (Figure 3). IL-10 and TGF-β1 expression did not
display any statistically signiﬁcant change in relation to the
intensity of inﬂammation. To this end, it must be noted
that no patients with NAFLD presented with moderate or
severe inﬂammation, that is, that all patients categorized as
I-3 and I-4 represent those with chronic viral hepatitis and
autoimmune cirrhosis (Table 1).
Moreover, a signiﬁcant positive correlation between
mRNA levels of Foxp3, FasL,a n dIFN-γ with ﬁbrosis
(P = .003, P = .004, and P = .013, resp.) was observed.
Interestingly, ﬁbrosis staging correlated negatively with the
expressionlevelsofIL-10(P = .003)andcaspase-3(P = .013),
but not with the expression of TGF-β1 and other apoptosis
mediators (P > .05). Furthermore, a signiﬁcant positive
correlation between the expression levels of IL-1β and those
of TNF-α and caspase-3 was also observed (P < .001 and P
< .001, resp.).
Finally, as expected, HAI score was positively correlated
with ALT levels (P = .038), in patients with CHB and CHC.
4. Discussion
Our study provides clear evidence that irrespective of the
cause of liver damage, Foxp3 expression, and not IL-10 and
TGF-β1, appeared with a dramatic increase that relates to
the intensity of liver inﬂammation. Moreover, apoptosis-
induced inﬂammation is observed in a wide range of liver
diseases.
It is well known that viruses sensitize hepatocytes to
apoptosiswhilsttheyarealsocapableofinhibitingit,inorder
to allow the survival of the infected host cells [21], as well
as that increased expression of Fas/FasL appears in chronic
viral hepatitis [22–27]. However, contradictory results exist
in the literature regarding their relation with inﬂammation
(HAIscore)andALTlevels[26–28].Accordingtoourresults,
a signiﬁcant increase of Fas and TRAIL appears at the early
stages of liver inﬂammation that could contribute to its
induction. As the inﬂammation exacerbates and striking
ﬁbrosis (cirrhosis) is established, the expression of these
apoptosis mediators declines. This ﬁnding can be attributed
to the evolution of liver damage followed by destruction
of hepatocytes and accumulation of lymphocytic inﬁltrate.
As such, the elevated FasL expression, mainly expressed
by CTLs, can also be explained, despite the fact that it is
not followed by a parallel increase of TRAIL expression, as
expected.
Most interestingly, however, our ﬁndings indicate that
not only apoptosis is taking place in NAFLD, but also it can
equally be responsible for the induction of inﬂammation,
considered till now to be associated with lipid-related NF-
κBa c t i v a t i o n[ 28, 29]. Notwithstanding the limited cases
examined with autoimmune hepatitis, PBC and MTX-
hepatotoxicity, the same phenomenon was observed. Till
now, there is only scarce evidence [30–33] that an increased
expressionofFas/FasLaccompaniesNAFLD.Thecovariation
of apoptosis mediators with inﬂammation that was observed
in our NAFLD patients represents a line of supporting
evidence to the results by Feldstein et al. [32], correlating
inﬂammation with TUNEL-positive cells in this disease.
As mentioned above, a high intrahepatic expression of
another death ligand activating the caspase cascade and
apoptosis, namely, TRAIL, was demonstrated. Although
TRAIL induces apoptosis mostly in transformed cells, recent
in vitro studies showed that it triggers steatosis and massive
apoptosis in fresh liver explants from patients with viral
hepatitis or fatty liver [34–37]. The increased intrahepatic
expressionofTRAILthatwefoundfollowedthesamepattern
of expression of Fas, indicating the signiﬁcant role that this
molecule might play in liver inﬂammation, irrespective of
the cause. The nature (soluble or transmembrane) and the6 Mediators of Inﬂammation
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Figure 2: Results of the Spearman’s rank correlation coeﬃcient between Foxp3 and TRAIL (a), Foxp3 and Fas (b), and Foxp3 and FasL (c),
in all disease subgroups considered.
source (immune cells or hepatocytes) of TRAIL as well as the
downstream molecules (receptors and mediators) activated
during its signalling in hepatocytes or stellate cells remain to
be determined.
We demonstrated that the intensity of chronic liver
inﬂammation was not associated with IL-1β expression, and
its mRNA levels were signiﬁcantly lower in patients with
CHB and CHC compared to normal controls. Moreover, a
strongpositivecorrelationoftheexpressionofproinﬂamma-
tory cytokines IL-1β and TNF-α was also observed. Interest-
ingly, our ﬁndings are in accordance with those of Bortolami
et al., whereas a lower expression of IL-1β in patients with
CHB and CHC compared to normal controls was also
reported [38]. A plausible explanation could be the accu-
mulation of lymphocyte inﬁltrate in chronic viral hepatitis,
resulting in altered cellularity with a low proportion of cells
producingtheaforementionedcytokines.Ontheotherhand,
a low production of the above proinﬂammatory cytokines
in chronic viral inﬂammation cannot be excluded. IL-1β
and TNF-α are prototypic cytokines that exert pleiotropic
eﬀects on a variety of cells, playing a fundamental role in
acute and chronic inﬂammatory conditions [39, 40]. Their
role at the initial phases of local and systemic inﬂammation,
triggering a complex network of signalling molecules, is
indisputable and well characterized [39, 40]. Moreover, a
sustained increased expression of IL-1β and TNF-α has
been reported in several cases of chronic local inﬂamma-
tion, as in rheumatoid arthritis and inﬂammatory bowel
diseases, where the anticytokine therapy is very eﬀective,
reducing symptoms and slowing or arresting tissue damage
[41]. However, in cases of severe systemic inﬂammation,
a downregulation of mRNA levels of the proinﬂammatory
cytokines IL-1β and TNF-α,p r o d u c e db yl i v e ra n db l o o d
cells, has been reported [41, 42]. As a result, the anticytokine
therapy for such patients is detrimental [41]. Our ﬁndings
may display that a similar phenomenon is observed inMediators of Inﬂammation 7
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Figure 3: Boxplot diagrams presenting the expression of Foxp3 and apoptosis mediators according to the intensity of liver inﬂammation
(classiﬁcation as presented in Section 2). Abscissa corresponds to relative mRNA expression. The pattern of expression in the Foxp3 diagram
followed also by FasL, but not by Fas and TRAIL. P value in each diagram refers to Kruskal-Wallis H test.
chronic liver inﬂammation, especially in cases of chronic
viral hepatitis. Thus, considering the sustained low levels of
the proinﬂammatory cytokines in patients with chronic viral
hepatitis as well as the fact that the anticytokine therapy for
rheumatoid arthritis and inﬂammatory bowel diseases can
also result in reactivation of HBV or HCV infections [43],
the contribution of an inappropriate inﬂammatory reaction
as the causative of the chronicity of viral infections should be
taken into account and remains to be determined.
Our results, regarding Foxp3, IL-10,a n dTGF-β1 expres-
sion, imply that nTregs, and not iTregs, could contribute by
processesunknownasyettoinﬂammatoryliverdisease.Most
intriguing is the ﬁnding that increased Foxp3 expression, and
therefore nTregs intrahepatic accumulation, characterizes
not only viral hepatitis but also to an equal degree, NAFLD
as well as autoimmune hepatitis, PBC and MTX-related
hepatotoxicity. Till now, the increased frequency of nTregs
in the peripheral blood and/or their accumulation in the
liver of patients with CHB or CHC has been attributed
to the expansion of Tregs modulating the function of
virus-speciﬁc T cells [8–11, 13]. Moreover, it has been
postulatedthatvirusescontributetotheproductionofvirus-
speciﬁc Tregs, suppressing the virus-speciﬁc T cell clones
and thus allowing the persistence of viral infections [6–
8,11].However,evidencesupportingthishypothesisremains
obscure. On the contrary, it has been described that in
mice, the depletion of nTregs leads to immunopathology
and deterioration of infectious diseases induced by various
pathogens [44, 45]. Indeed, Wei et al. demonstrated that the
depletion of FOXP3+ Tregs results in fulminant hepatitis in
a mouse model of immune-mediated liver damage (induced
by Concanavalin A) [46]. According to our results, persistent8 Mediators of Inﬂammation
liver inﬂammation, regardless of its cause, seems to represent
a main factor that contributes to the expansion of nTregs.
Should this be the case, then the described suppression of
virus-speciﬁcTcellscouldbeconsideredasabystandereﬀect
of the nTregs that have been expanded due to the persistent
apoptosis-induced inﬂammation.
Taken collectively, our results are in line with the
attractive view of Zheng and Rudensky claiming that Tregs
“have a vital role in preventing autoimmunity and pathology
inﬂicted by uncontrolled immune responses to infections”
[1]. As such, the evidence provided by our work can be
integrated in a comprehensive protective model as detailed
below. The excessive apoptosis induced by various tissue
insults may overcome the capability of macrophages to
safely clear the apoptotic cells. Consequently, the emergence
of inﬂammation cannot be prevented by the secretion of
anti-inﬂammatory cytokines from macrophages. In parallel,
excessive autoantigen presentation is taking place leading
to the activation of autoreactive T cells. Pre existing nTreg
clones are therefore expanded, in order to prevent the self-
tissue damage and to avoid catastrophic pathology.
Recent animal and human studies demonstrated that
intrahepatic Tregs were increased in autoimmune liver
diseases [47, 48], considering also that in AIH they were
found fewer than in PBC, estimated by immunocytochem-
istry [47]. Despite the fact that our work provides also
limited, yet consistent, data with regard to the autoimmune
hepatitis/cirrhosis and PBC, it can be postulated that, in
these cases, apoptosis-induced inﬂammation might be the
result,ratherthanthecause,oftheautoimmunedamagethat
might have initiated due to a defective nTreg function. This
being the case, the above initiates and perpetuates a vicious
cycleleadingtothedestructionofself-tissues.Inotherwords,
our model indicates that Tregs could be the missing link to
the “waste disposal” hypothesis of autoimmunity [49].
Should a similar protective role of nTregs be uncovered
in other types of apoptosis-induced inﬂammation, then the
proposed targeting of apoptosis [50], rather than of nTregs,
could prove to be a more promising therapeutic modality.
Our results and the pathophysiological model we propose
conﬁrm that, possibly with the exception of autoimmunity,
nTregs represent a protective mechanism whose manip-
ulation should be carefully considered. However, further
research towards the elucidation of the underlying casual
relationships is required, in order to clarify whether our
ﬁndings signify the existence of a uniform Treg-mediated
regulatory mechanism of apoptosis-induced inﬂammation.
Acknowledgments
This study was supported by grants from the “Hellenic Soci-
ety for the Study of the Liver” and the “Basic Research Schol-
arship Hrakleitos-II, National Strategic Reference Frame-
work 2007–2013, Greece.”
References
[1] Y. Zheng and A. Y. Rudensky, “Foxp3 in control of the
regulatory T cell lineage,” Nature Immunology, vol. 8, no. 5,
pp. 457–462, 2007.
[2] K. J. Maloy and F. Powrie, “Regulatory T cells in the control
of immune pathology,” Nature Immunology,v o l .2 ,n o .9 ,p p .
816–822, 2001.
[3] J. M. Kim, J. P. Rasmussen, and A. Y. Rudensky, “Regulatory
T cells prevent catastrophic autoimmunity throughout the
lifespan of mice,” Nature Immunology, vol. 8, no. 2, pp. 191–
197, 2007.
[4] S. Jiang, N. Camara, G. Lombardi, and R. I. Lechler, “Induc-
tion of allopeptide-speciﬁc human CD4+CD25+ regulatory T
cells ex vivo,” Blood, vol. 102, no. 6, pp. 2180–2186, 2003.
[5] E. M. Aandahl, J. Micha¨ elsson, W. J. Moretto, F. M. Hecht,
a n dD .F .N i x o n ,“ H u m a nC D 4 +CD25+ Regulatory T Cells
Control T-Cell Responses to Human Immunodeﬁciency Virus
and Cytomegalovirus Antigens,” Journal of Virology, vol. 78,
no. 5, pp. 2454–2459, 2004.
[6] K. Sugimoto, F. Ikeda, J. Stadanlick, F. A. Nunes, H. J.
Alter, and K. M. Chang, “Suppression of HCV-speciﬁc T
cells without diﬀerential hierarchy demonstrated ex vivo in
persistent HCV infection,” Hepatology, vol. 38, no. 6, pp.
1437–1448, 2003.
[7] R. Cabrera, Z. Tu, Y. Xu et al., “An immunomodulatory role
for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus
infection,” Hepatology, vol. 40, no. 5, pp. 1062–1071, 2004.
[8] J.N.Stoop,R.G.VanDerMolen,C.C.Baanetal.,“Regulatory
T cells contribute to the impaired immune response in
patients with chronic hepatitis B virus infection,” Hepatology,
vol. 41, no. 4, pp. 771–778, 2005.
[9] D. Xu, J. Fu, L. Jin et al., “Circulating and liver resident
CD4+CD25+ regulatory T cells actively inﬂuence the antiviral
immune response and disease progression in patients with
hepatitis B,” Journal of Immunology, vol. 177, no. 1, pp. 739–
747, 2006.
[10] S. M. Ward, B. C. Fox, P. J. Brown et al., “Quantiﬁcation
and localisation of FOXP3+ T lymphocytes and relation to
hepatic inﬂammation during chronic HCV infection,” Journal
of Hepatology, vol. 47, no. 3, pp. 316–324, 2007.
[11] O. Franzese, P. T. F. Kennedy, A. J. Gehring et al., “Modulation
oftheCD8+-T-cellresponsebyCD4+ CD25+ regulatoryTcells
inpatientswithhepatitisBvirusinfection,”JournalofVirology,
vol. 79, no. 6, pp. 3322–3328, 2005.
[12] T. Manigold and V. Racanelli, “T-cell regulation by CD4
regulatory T cells during hepatitis B and C virus infections:
facts and controversies,” Lancet Infectious Diseases, vol. 7, no.
12, pp. 804–813, 2007.
[13] J. F. R. Kerr, W. G. E. Cooksley, J. Searle et al., “The nature of
piecemeal necrosis in chronic active hepatitis,” Lancet, vol. 2,
no. 8147, pp. 827–828, 1979.
[14] C. Rust and G. J. Gores, “Apoptosis and liver disease,” Ameri-
can Journal of Medicine, vol. 108, no. 7, pp. 567–574, 2000.
[15] H. Jonuleit and E. Schmitt, “The regulatory T cell
family: distinct subsets and their interrelations,” Journal
of Immunology, vol. 171, no. 12, pp. 6323–6327, 2003.
[16] K. Ishak, A. Baptista, L. Bianchi et al., “Histological grading
and staging of chronic hepatitis,” Journal of Hepatology, vol.
22, no. 6, pp. 696–699, 1995.
[ 1 7 ]E .M .B r u n t ,C .G .J a n n e y ,A .M .D iB i s c e g l i e ,B .A .
Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic
steatohepatitis: a proposal for grading and staging the
histological lesions,” American Journal of Gastroenterology,
vol. 94, no. 9, pp. 2467–2474, 1999.
[18] J. Ludwig, E. R. Dickson, and G. S.A. McDonald, “Staging of
chronic nonsuppurative destructive cholangitis (syndrome of
primary biliary cirrhosis),” Virchows Archiv, vol. 379, no. 2,
pp. 103–112, 1978.Mediators of Inﬂammation 9
[19] P. Scheuer, “Primary biliary cirrhosis,” Proceedings of the Royal
Society of Medicine, vol. 60, no. 12, pp. 1257–1260, 1967.
[20] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene
expression data using real-time quantitative PCR and the 2T
method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
[21] J. G. Teodoro and P. E. Branton, “Regulation of apoptosis by
viral gene products,” Journal of Virology,v o l .7 1 ,n o .3 ,p p .
1739–1746, 1997.
[22] P. R. Galle, W. J. Hofmann, H. Walczak et al., “Involvement
of the CD95 (APO-1/Fas) receptor and ligand in liver
damage,” Journal of Experimental Medicine, vol. 182, no. 5, pp.
1223–1230, 1995.
[23] K. Mochizuki, N. Hayashi, N. Hiramatsu et al., “Fas antigen
expression in liver tissues of patients with chronic hepatitis
B,” Journal of Hepatology, vol. 24, no. 1, pp. 1–7, 1996.
[24] K. X. Luo, Y. F. Zhu, L. X. Zhang, H. T. He, X. S. Wang, and L.
Zhang, “In situ investigation of Fas/FasL expression in chronic
hepatitis B infection and related liver diseases,” Journal of Viral
Hepatitis, vol. 4, no. 5, pp. 303–307, 1997.
[25] C. M. P. Rodrigues, D. Brites, F. Serejo, A. Costa, F. Ramalho,
and M. Carneiro De Moura, “Apoptotic cell death does not
parallel other indicators of liver damage in chronic hepatitis c
patients,” Journal of Viral Hepatitis, vol. 7, no. 3, pp. 175–183,
2000.
[26] M.Tagashira,K.Yamamoto,K.Fujioetal.,“Expressionofper-
forinandFasligandmRNAintheliverofviralhepatitis,”Jour-
nal of Clinical Immunology, vol. 20, no. 5, pp. 347–353, 2000.
[27] J. Y. Lee, D. W. Chae, S. M. Kim et al., “Expression of FasL
and perforin/granzyme B mRNA in chronic hepatitis B
virus infection,” Journal of Viral Hepatitis,v o l .1 1 ,n o .2 ,p p .
130–135, 2004.
[ 2 8 ]P .A .K e r n ,M .S a g h i z a d e h ,J .M .O n g ,R .J .B o s c h ,R .D e e m ,
a n dR .B .S i m s o l o ,“ T h ee x p r e s s i o no ft u m o rn e c r o s i sf a c t o r
in human adipose tissue. Regulation by obesity, weight loss,
and relationship to lipoprotein lipase,” Journal of Clinical
Investigation, vol. 95, no. 5, pp. 2111–2119, 1995.
[29] I. Copaci, L. Micu, and M. Voiculescu, “The role of cytokines
in non-alcoholic steatohepatitis. A systematic review,” Journal
of Gastrointestinal and Liver Diseases,v o l .1 5 ,n o .4 ,p p .
363–373, 2006.
[ 3 0 ]Q .C h e n ,M .G a l l e a n o ,a n dA .I .C e d e r b a u m ,“ C y t o t o x i c i t y
and apoptosis produced by arachidonic acid in Hep G2 cells
overexpressing human cytochrome P4502E1,” Journal of
Biological Chemistry, vol. 272, no. 23, pp. 14532–14541, 1997.
[31] T. Yamauchi, J. Kamon, Y. Minokoshi et al., “Adiponectin
stimulates glucose utilization and fatty-acid oxidation by
activating AMP-activated protein kinase,” Nature Medicine,
vol. 8, no. 11, pp. 1288–1295, 2002.
[32] A. E. Feldstein, A. Canbay, P. Angulo et al., “Hepatocyte
apoptosis and Fas expression are prominent features of
human nonalcoholic steatohepatitis,” Gastroenterology, vol.
125, no. 2, pp. 437–443, 2003.
[33] Z. Li, J. A. Oben, S. Yang et al., “Norepinephrine regulates
hepatic innate immune system in leptin-deﬁcient mice with
nonalcoholic steatohepatitis,” Hepatology,v o l .4 0 ,n o .2 ,p p .
434–441, 2004.
[34] A. H. Chou, H. F. Tsai, Y. Y. Wu et al., “Hepatitis C virus core
protein modulates TRAIL-mediated apoptosis by enhancing
bid cleavage and activation of mitochondria apoptosis
signaling pathway,” Journal of Immunology, vol. 174, no. 4, pp.
2160–2166, 2005.
[35] B. Mundt, T. Wirth, L. Lender et al., “Tumour necrosis factor
related apoptosis inducing ligand (TRAIL) induces hepatic
steatosis in viral hepatitis and after alcohol intake,” Gut, vol.
54, no. 11, pp. 1590–1596, 2005.
[ 3 6 ]H .M a l h i ,F .J .B a r r e y r o ,H .I s o m o t o ,S .F .B r o n k ,a n dG .J .
Gores, “Free fatty acids sensitise hepatocytes to TRAIL medi-
ated cytotoxicity,” Gut, vol. 56, no. 8, pp. 1124–1131, 2007.
[37] X. Volkmann, U. Fischer, M. J. Bahr et al., “Increased
hepatotoxicity of tumor necrosis factor-related apoptosis-
inducing ligand in diseased human liver,” Hepatology, vol. 46,
no. 5, pp. 1498–1508, 2007.
[38] M.Bortolami,A.Kotsafti,R.Cardin,andF.Farinati,“Fas/FasL
system, IL-1β expression and apoptosis in chronic HBV and
HCV liver disease,” Journal of Viral Hepatitis, vol. 15, no. 7,
pp. 515–522, 2008.
[ 3 9 ]M .K o l b ,P .J .M a r g e t t s ,D .C .A n t h o n y ,F .P i t o s s i ,a n dJ .
Gauldie, “Transient expression of IL-1β induces acute lung
injury and chronic repair leading to pulmonary ﬁbrosis,”
Journal of Clinical Investigation, vol. 107, no. 12, pp. 1529–
1536, 2001.
[40] C.E.McCallandB.K.Yoza,“Genesilencinginseveresystemic
inﬂammation,” American Journal of Respiratory and Critical
Care Medicine, vol. 175, no. 8, pp. 763–767, 2007.
[41] A. P. Cope and M. Feldmann, “Emerging approaches for the
therapy of autoimmune and chronic inﬂammatory disease,”
Current Opinion in Immunology, vol. 16, no. 6, pp. 780–786,
2004.
[42] C. J. Wrighton, R. Hofer-Warbinek, T. Moll, R. Eytner,
F. H. Bach, and R. De Martin, “Inhibition of endothelial
cell activation by adenovirus-mediated expression of IκBα,
an inhibitor of the transcription factor NF-κB,” Journal of
Experimental Medicine, vol. 183, no. 3, pp. 1013–1022, 1996.
[43] M. B. Carroll and M. I. Bond, “Use of tumor necrosis factor-α
inhibitors in patients with chronic hepatitis B infection,”
Seminars in Arthritis and Rheumatism,v o l .3 8 ,n o .3 ,p p .
208–217, 2008.
[44] A. Aseﬀa, A. Gumy, P. Launois, H. R. MacDonald, J. A.
Louis, and F. Tacchini-Cottier, “The early IL-4 response to
Leishmania major and the resulting Th2 cell maturation
steering progressive disease in BALB/c mice are subject to
the control of regulatory CD4+CD25+ Tc e l l s , ”Journal of
Immunology, vol. 169, no. 6, pp. 3232–3241, 2002.
[45] S. Hori, T. L. Carvalho, and J. Demengeot, “CD25+CD4+
regulatory T cells suppress CD4+ T cell-mediated pulmonary
hyperinﬂammation driven by Pneumocystis carinii in
immunodeﬁcient mice,” European Journal of Immunology, vol.
32, no. 5, pp. 1282–1291, 2002.
[46] H. X. Wei, YA. H. Chuang, B. Li et al., “CD4+CD25+ Foxp3+
regulatory T cells protect against T cell-mediated fulminant
hepatitis in a TGF-β-dependent manner in mice,” Journal of
Immunology, vol. 181, no. 10, pp. 7221–7229, 2008.
[47] M. Sakaki, K. Hiroishi, T. Baba et al., “Intrahepatic status of
regulatory T cells in autoimmune liver diseases and chronic
viral hepatitis,” Hepatology Research,v o l .3 8 ,n o .4 ,p p .
354–361, 2008.
[48] C. Saeki, M. Nakano, H. Takahashi et al., “Accumulation
of functional regulatory T cells in actively inﬂamed liver in
mouse dendritic cell-based autoimmune hepatic inﬂamma-
tion,” Clinical Immunology, vol. 135, no. 1, pp. 156–166, 2010.
[49] M. J. Walport, “Complement. Second of two parts,” New Eng-
landJournalofMedicine,vol.344,no.15,pp.1140–1144,2001.
[50] T. Kondo, T. Suda, H. Fukuyama, M. Adachi, and S. Nagata,
“Essential roles in the Fas ligand in the development of
hepatitis,” Nature Medicine, vol. 3, no. 4, pp. 409–413, 1997.